Hakan Widner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12074026/publications.pdf

Version: 2024-02-01

81900 91884 11,165 77 39 69 citations g-index h-index papers 80 80 80 8033 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort. Journal of Parkinson's Disease, 2022, 12, 153-171.	2.8	5
2	Parkinson's disease laterality: a 11C-PE2I PET imaging study. Journal of Neurology, 2021, 268, 582-589.	3.6	3
3	Transforming trash to treasure Cultural ambiguity in foetal cell research. Philosophy, Ethics, and Humanities in Medicine, 2021, 16, 6.	1.5	0
4	Genetically Targeted Clinical Trials in Parkinson's Disease: Learning from the Successes Made in Oncology. Genes, 2021, 12, 1529.	2.4	2
5	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	2.2	12
6	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. Neuroradiology, 2018, 60, 247-254.	2.2	23
7	¹¹ Câ€PE2I and ¹⁸ Fâ€Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 2018, 33, 117-127.	3.9	45
8	P3â€270: CEREBROSPINAL FLUID CONCENTRATIONS OF INFLAMMATORY MARKERS IN PARKINSON'S DISEASE AND ATYPICAL PARKINSONIAN DISORDERS. Alzheimer's and Dementia, 2018, 14, P1180.	0.8	0
9	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	2.2	17
10	In vivo retention of ¹⁸ F-AV-1451 in corticobasal syndrome. Neurology, 2017, 89, 845-853.	1.1	103
11	[ICâ€Pâ€199]: [18]Fâ€AVâ€1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION. Alzheimer's a Dementia, 2017, 13, P146.	and 0.8	0
12	Initiation of Levodopa-Carbidopa IntestinalÂGel Infusion Using Telemedicine (Video Communication) Tj ETQq0 0 C Disease. Journal of Parkinson's Disease, 2017, 7, 719-728.	O rgBT /Ove 2.8	erlock 10 Tf 5 29
13	Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6544-6549.	7.1	235
14	Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism and Related Disorders, 2016, 29, 17-23.	2.2	43
15	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders, 2016, 31, 1020-1026.	3.9	49
16	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. PLoS ONE, 2016, 11, e0157755.	2.5	35
17	Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain, 2015, 138, 963-973.	7.6	140
18	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Neuroradiology, 2015, 57, 1079-1091.	2.2	37

#	Article	IF	CITATIONS
19	Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease. JAMA Neurology, 2014, 71, 83.	9.0	257
20	The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurology, The, 2013, 12, 264-274.	10.2	426
21	Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy. PLoS ONE, 2013, 8, e62354.	2.5	40
22	Accuracy and Sensitivity of Parkinsonian Disorder Diagnoses in Two Swedish National Health Registers. Neuroepidemiology, 2012, 38, 186-193.	2.3	58
23	First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation. Parkinsonism and Related Disorders, 2012, 18, 332-338.	2.2	40
24	Signs of Degeneration in 12–22-Year Old Grafts of Mesencephalic Dopamine Neurons in Patients with Parkinson's Disease. Journal of Parkinson's Disease, 2011, 1, 83-92.	2.8	90
25	Characterization of Lewy body pathology in 12―and 16â€ y earâ€old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Movement Disorders, 2010, 25, 1091-1096.	3.9	181
26	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. Movement Disorders, 2010, 25, 2604-2612.	3.9	205
27	Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus?. Parkinsonism and Related Disorders, 2009, 15, 390-392.	2.2	29
28	A Swedish family with de novo \hat{l}_{\pm} -synuclein A53T mutation: Evidence for early cortical dysfunction. Parkinsonism and Related Disorders, 2009, 15, 627-632.	2.2	101
29	Red flags for multiple system atrophy. Movement Disorders, 2008, 23, 1093-1099.	3.9	215
30	Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine, 2008, 14, 501-503.	30.7	1,595
31	Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiology of Aging, 2008, 29, 1765-1773.	3.1	27
32	Fulfilment of patients' goals after thalamic deep brain stimulation: A follow-up study. Parkinsonism and Related Disorders, 2007, 13, 29-34.	2.2	9
33	Measuring Fatigue in Parkinson's Disease: A Psychometric Study of Two Brief Generic Fatigue Questionnaires. Journal of Pain and Symptom Management, 2006, 32, 420-432.	1.2	97
34	Healthâ€related quality of life in multiple system atrophy. Movement Disorders, 2006, 21, 809-815.	3.9	102
35	Immune problems in central nervous system cell therapy. NeuroRx, 2004, 1, 472-481.	6.0	169
36	Intracerebral cytokine profiles in adult rats grafted with neural tissue of different immunological disparity. Brain Research Bulletin, 2004, 63, 105-118.	3.0	29

#	Article	IF	Citations
37	Immune problems in central nervous system cell therapy. Neurotherapeutics, 2004, 1, 472-481.	4.4	О
38	Longâ€term efficacy of thalamic deep brain stimulation for tremor: Doubleâ€blind assessments. Movement Disorders, 2003, 18, 163-170.	3.9	285
39	Activated Porcine Embryonic Brain Endothelial Cells Induce a Proliferative Human T-Lymphocyte Response. Cell Transplantation, 2003, 12, 637-646.	2.5	7
40	Induction of operational tolerance to discordant dopaminergic porcine xenografts1. Transplantation, 2003, 75, 1448-1454.	1.0	24
41	Strategies to modify levodopa treatment. Advances in Neurology, 2003, 91, 229-36.	0.8	4
42	Clinical neurotransplantation: Core assessment protocol rather than sham surgery as control. Brain Research Bulletin, 2002, 58, 547-553.	3.0	29
43	Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of discordant neural xenografts in mice lacking CD40L. Xenotransplantation, 2002, 9, 68-76.	2.8	25
44	Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience, 2002, 5, 627-628.	14.8	424
45	Porcine Neural Xenografts in Rats and Mice: Donor Tissue Development and Characteristics of Rejection. Experimental Neurology, 2001, 172, 100-114.	4.1	57
46	Enhanced Survival of Porcine Neural Xenografts in Mice Lacking CD1d1, But No Effect of NK1.1 Depletion. Cell Transplantation, 2001, 10, 295-304.	2.5	25
47	Intrastriatal Ventral Mesencephalic Xenografts of Porcine Tissue in Rats: Immune Responses and Functional Effects. Cell Transplantation, 2000, 9, 261-272.	2.5	63
48	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology, 2000, 48, 689-695.	5.3	246
49	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Movement Disorders, 2000, 15, 224-229.	3.9	47
50	Neural Tissue Xenotransplantation: What is Needed Prior to Clinical Trials in Parkinson's Disease?. Cell Transplantation, 2000, 9, 235-246.	2.5	36
51	Chapter 8 Xenotransplantation. Progress in Brain Research, 2000, 127, 157-188.	1.4	6
52	Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them. Trends in Neurosciences, 2000, 23, 337-344.	8.6	70
53	Differential effects of Bcl-2 overexpression on fibre outgrowth and survival of embryonic dopaminergic neurons in intracerebral transplants. European Journal of Neuroscience, 1999, 11, 3073-3081.	2.6	39
54	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience, 1999, 2, 1137-1140.	14.8	663

#	Article	IF	CITATIONS
55	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Medicine, 1999, 5, 97-100.	30.7	279
56	Clinical rating of dyskinesias in Parkinson's disease: Use and reliability of a new rating scale. Movement Disorders, 1999, 14, 448-455.	3.9	87
57	Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Movement Disorders, 1999, 14, 572-584.	3.9	724
58	Discordant xenografts: different outcome after mouse and rat neural tissue transplantation to guinea-pigs. Brain Research Bulletin, 1999, 49, 367-376.	3.0	12
59	Human Natural Antibodies Cytotoxic to Pig Embryonic Brain Cells Recognize Novel Non-Gall $\pm 1,3$ Gal-Based Xenoantigens. Experimental Neurology, 1999, 159, 347-361.	4.1	33
60	Porcine Embryonic Brain Cell Cytotoxicity Mediated by Human Natural Killer Cells. Cell Transplantation, 1999, 8, 601-610.	2.5	20
61	Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. European Journal of Neuroscience, 1998, 10, 2595-2606.	2.6	38
62	Immunological Issues in Rodent and Primate Transplants (Allografts). , 1998, , 171-187.		1
63	The Lund Transplant Program for Parkinson's Disease and Patients with MPTP-Induced Parkinsonism. , 1998, , 1-17.		6
64	Rat Intrastriatal Neural Allografts Challenged with Skin Allografts at Different Time Points. Experimental Neurology, 1997, 148, 334-347.	4.1	20
65	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology, 1997, 42, 95-107.	5.3	331
66	Methylprednisolone prevents rejection of intrastriatal grafts of xenogeneic embryonic neural tissue in adult rats. Brain Research, 1996, 712, 199-212.	2.2	26
67	Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Medicine, 1995, 1, 226-231.	30.7	146
68	Using Fetal Mesencephalic Grafts to Treat MPTP-Induced Parkinsonism., 1995,, 231-239.		0
69	Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Annals of Neurology, 1994, 35, 172-180.	5. 3	412
70	Sequential Intracerebral Transplantation of Allogeneic and Syngeneic Fetal Dopamine-Rich Neuronal Tissue in Adult Rats: Will the First Graft be Rejected?. Cell Transplantation, 1993, 2, 307-317.	2.5	69
71	Expression of Platelet-Derived Growth Factor in and around Intrastriatal Embryonic Mesencephalic Grafts. Cell Transplantation, 1993, 2, 151-162.	2.5	11
72	Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by 1-Methyl-4-Phenyl-L,2,3,6-Tetrahydropyridine (MPTP). New England Journal of Medicine, 1992, 327, 1556-1563.	27.0	558

#	Article	IF	Citations
73	Core assessment program for intracerebral transplantations (CAPIT). Movement Disorders, 1992, 7, 2-13.	3.9	874
74	Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neurophysiological observations in two patients with putaminal implants. Annals of Neurology, 1992, 31, 155-165.	5.3	359
75	Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6-L-fluorodopa studies in two patients with putaminal implants. Annals of Neurology, 1992, 31, 166-173.	5.3	304
76	Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Research Reviews, 1988, 13, 287-324.	9.0	342
77	Immunological Issues in Rodent and Primate Transplants (Allografts). , 0, , 171-188.		4